

Active Lives, Stronger Kidneys: How Exercise Shapes Cognitive and Cardiorenal Health in Chronic Kidney Disease



Wei-Cheng Tseng, MD, PhD

Division of Nephrology, Taipei Veterans General Hospital
School of Medicine, National Yang Ming Chiao Tung University




Disclaimer


- No conflict of interests

Outlines

- Physical activity (PA)
 - Benefit
- Muscle kidney crosstalk
- PA in CKD
 - Pathophysiology
 - Outcomes
- Interaction between PA and Cognitive Impairment in CKD



CV Risk Factors in CKD



Panel 1: Health benefits of physical activity in adults³⁻⁵

Strong evidence of reduced rates of:

- All-cause mortality
- Coronary heart disease
- High blood pressure
- Stroke
- Metabolic syndrome
- Type 2 diabetes
- Breast cancer
- Colon cancer
- Depression
- Falling



Strong evidence of:

- Increased cardiorespiratory and muscular fitness
- Healthier body mass and composition
- Improved bone health
- Increased functional health
- Improved cognitive function

- ✓ **6-10%** of all deaths from noncommunicable diseases attributable to **physical inactivity**
- ✓ **4th** leading cause of death worldwide



Every Move Counts



1 MET=1 kcal/kg/hr; MET-hr=Volume

Physical activity	MET
Light intensity activities	< 3
sleeping	0.9
watching television	1.0
writing, desk work, typing	1.8
walking, 1.7 mph (2.7 km/h), level ground, strolling, very slow	2.3
walking, 2.5 mph (4 km/h)	2.9
Moderate intensity activities	3 to 6
bicycling, stationary, 50 watts, very light effort	3.0
walking 3.0 mph (4.8 km/h)	3.3
calisthenics, home exercise, light or moderate effort, general	3.5
walking 3.4 mph (5.5 km/h)	3.6
bicycling, <10 mph (16 km/h), leisure, to work or for pleasure	4.0
bicycling, stationary, 100 watts, light effort	5.5
Vigorous intensity activities	> 6
jogging, general	7.0
calisthenics (e.g. pushups, situps, pullups, jumping jacks), heavy, vigorous effort	8.0
running jogging, in place	8.0
rope jumping	10.0

1 hr

30 min

NHANES-II: Low PA links to risks of CKD

TABLE 3. Relative Risks for Chronic Kidney Disease Associated with Lifestyle Behaviors and Obesity

N = 9082	Model 1 [†]		Model 2 [‡]		Model 3 [§]	
	RR	95% CI	RR	95% CI	RR	95% CI
Physical activity						
High*	1.0		1.0		1.0	
Moderate	1.2	0.7–1.8	1.1	0.7–1.7	1.2	0.7–2.0
Low	2.2	1.3–3.8	1.8	1.0–3.3	2.2	1.2–4.1
Smoking						
Never*	1.0		1.0		1.0	
Former	0.9	0.6–1.3	0.9	0.6–1.4	0.8	0.5–1.2
Current						
1–20 cigarettes/day	1.2	0.7–2.3	1.4	0.7–2.7	0.9	0.5–1.9
> 20 cigarettes/day	2.3	1.3–4.2	2.3	1.2–4.3	2.6	1.4–4.7
Alcohol consumption						
Never*	1.0		1.0		1.0	
Seldom	0.7	0.4–1.2	0.8	0.4–1.4	0.5	0.3–1.0
Weekly	0.7	0.5–1.1	0.9	0.6–1.3	0.9	0.6–1.3
Daily	0.9	0.5–1.5	0.9	0.5–1.6	0.9	0.4–2.2
Body mass index (kg/m ²)						
Thin (<18.5)	1.3	0.5–3.1	1.6	0.7–3.9	1.0	0.2–3.8
Normal (18.5–24)*	1.0		1.0		1.0	
Overweight (25–29)	0.9	0.5–1.5	0.7	0.4–1.3	0.7	0.4–1.3
Obese (30–34)	1.0	0.6–1.8	0.7	0.4–1.3	0.7	0.4–1.4
Morbid obesity (≥ 35)	2.3	1.1–4.9	1.3	0.6–2.9	1.7	0.6–4.5

CKD definition:

1. ESRD

2. Death related to CKD

Risk of ESRD by Amount of Leisure-Time Physical Activity

N = 245,639 Taiwanese, health checkup participants, average eGFR 91.3

MET-hr	Physical activity	No.	Person-years	No. of ESRD	HR1 ^b	(95% CI)	HR2 ^c	(95% CI)	HR3 ^d	(95% CI)
<3.75	No reported LTPA	245,639	3,297,765	1336	1.00		1.00		1.00	
3.75-7.49	Low	122,437	1,457,626	467	0.85	(0.76-0.95)	0.93	(0.83-1.05)	0.93	(0.82-1.04)
7.5-16.49	Medium	70,818	880,996	401	0.79	(0.70-0.89)	0.87	(0.77-0.99)	0.94	(0.83-1.07)
16.5-25.49	High	27,299	378,841	222	0.74	(0.63-0.86)	0.81	(0.69-0.95)	0.87	(0.74-1.02)
>= 25.5	Very high	16,342	228,315	94	0.57	(0.45-0.71)	0.68	(0.53-0.85)	0.72	(0.57-0.91)
<i>P</i> for trend					<.001		<.001		.003	
Medium or above		114,459	1,488,152	717	0.74	(0.67-0.82)	0.82	(0.74-0.91)	0.88	(0.80-0.98)

^aESRD, end-stage renal disease; HR, hazard ratio; LTPA, leisure-time physical activity.

^bHR1 adjusted for age and sex.

^cHR2 adjusted for age, sex, education, occupational activity, smoking status, drinking status, body mass index, diabetes, hypertension, hyperlipidemia, history of cardiovascular diseases, history of cancer, long-term use of herbal medicine, and long-term use of pain medications.

^dHR3 additionally adjusted for estimated glomerular filtration rate and proteinuria.

Outlines

- Physical activity (PA)
 - Benefit
- Muscle kidney crosstalk
- PA in CKD
 - Pathophysiology
 - Outcomes
- Interaction between PA and Cognitive Impairment in CKD

Muscle-Kidney crosstalk

Role of **secretome**
in kidney regeneration/growth

www.jasn.org

EDITORIALS

Can Muscle-Kidney Crosstalk Slow Progression of CKD?

Helbert Rondon-Berrios,* Yanlin Wang,† and
William E. Mitch†

*Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and

†Nephrology Division, Department of Medicine, Baylor College of Medicine, Houston, Texas

J Am Soc Nephrol 25: 2681–2683, 2014.
doi: 10.1681/ASN.2014060566

The skeletal muscle secretome: an emerging player in muscle–bone crosstalk





Table 1 Growth factors, cytokines and other peptides secreted by muscle, the factors that influence their secretion and their potential effects on bone metabolism

<i>Muscle-derived peptides</i>	<i>Factors that stimulate peptide secretion</i>	<i>Role(s) in bone metabolism</i>
<i>Growth factors</i>		
IGF-1	Resistance exercise	Stimulates bone formation
FGF-2	Eccentric muscle contraction	Stimulates bone formation
GDF-8	Muscle damage, cachexia, atrophy	Suppresses chondrogenesis and fracture healing
<i>Extracellular matrix molecules</i>		
SPARC	Resistance exercise, muscle regeneration	Promotes bone mineralization
MMP-2	Resistance exercise and re-loading	Fracture callus remodeling, bone formation
BMP-1	Blast trauma to muscle	Cleaving of procollagen and possibly heterotopic ossification
<i>Inflammatory cytokines</i>		
IL-6	Physical activity and muscle contraction	Bone resorption and turnover
IL-7	Physical activity and muscle contraction	Bone resorption
IL-15	Resistance exercise	Increase bone mass, decrease adiposity

Abbreviation: IL, interleukin.

Skeletal Muscle: a gene regulatory endocrine organ




Exercise increases PGC-1 α and Irisin



Iris

Messenger who delivered news from the gods





PGC-1 α : peroxisome proliferator-activated receptor gamma coactivator-1 α ; FNDC5: fibronectin type III domain containing 5; UCP-1: uncoupling protein-1.

Eat Weight Disord. 2018;23:431-42




Diabetes. 2014;63:381-3

Cell Metab. 2012;15:277-8

Smad3 negatively regulates PGC-1 α and serum irisin




Muscle-specific PGC-1 α overexpression \downarrow renal fibrosis





Outlines

- Physical activity (PA)
 - Benefit
- Muscle kidney crosstalk
- PA in CKD
 - Pathophysiology
 - Outcomes
- Interaction between PA and Cognitive Impairment in CKD




PA on inflammation, ROS, metabolism and vascular functions in CKD




A large, abstract circular graphic in the background, composed of a dark blue center and a surrounding ring of white and light blue splatters and dots, resembling a stylized Earth or a microscopic view of a cell.

Effects of PA on outcome in real-world CKD patients

Physical Activity and Mortality in Chronic Kidney Disease (NHANES III)



Association between Physical activity by Accelerometer and Mortality



*Each line represents 2 min/hr more in a separate model without adjustment for other activity durations

**Adjusted for age, gender, race, education, smoking, alcohol use, lung disease and mobility limitations

Clin J Am Soc Nephrol
2015 Jul 7;10(7):1145-53


Dose-response effects of physical activity on major adverse cardiorenal outcomes in CKD

N = 4508 CKD (eGFR < 45 or UPCR \geq 1 g/g)

Physical activity assessed by the NHANES questionnaire

A


All-cause mortality and ESRD



No. at Risk							
Highly-active	1915	997	560	307	125	36	16
Low-active	879	372	167	94	40	11	4
Inactive	1714	736	399	216	96	25	5

B

Major adverse cardiovascular events



No. at Risk							
Highly-active	1915	989	565	302	121	35	15
Low-active	879	363	162	90	40	10	4
Inactive	1714	729	417	234	101	26	5

Dose-response effects of physical activity on major adverse cardiorenal outcomes in CKD

Characteristics	Physical activity			P value	P value
	Inactive (0 MET-h/week)	Low-active (0 to <7.5 MET-h/week)	Highly active (≥7.5 MET-h/week)		
Participants, N (%)	1714 (38.0)	879 (19.5)	1915 (42.5)		
All-cause mortality and ESRD					
Event, N (%)	705 (41.1)	289 (32.9)	563 (29.4)		
Age and sex-adjusted HR (95% CI)	Reference	0.86 (0.75–0.98)	0.64 (0.57–0.71)	0.03	<0.001
Fully adjusted HR (95% CI) ^a	Reference	0.92 (0.80–1.05)	0.75 (0.67–0.84)	0.22	<0.001
All-cause mortality					
Event, N (%)	339 (19.8)	130 (14.8)	270 (14.1)		
Age and sex-adjusted HR (95% CI)	Reference	0.79 (0.64–0.97)	0.54 (0.46–0.64)	0.02	<0.001
Fully adjusted HR (95% CI) ^a	Reference	0.86 (0.70–1.06)	0.62 (0.53–0.74)	0.16	<0.001
ESRD					
Event, N (%)	486 (28.4)	196 (22.3)	377 (19.7)		
Age and sex-adjusted HR (95% CI)	Reference	0.87 (0.74–1.03)	0.68 (0.59–0.78)	0.10	<0.001
Fully adjusted HR (95% CI) ^a	Reference	0.93 (0.78–1.10)	0.83 (0.72–0.96)	0.38	0.01
MACE					
Event, N (%)	237 (13.8)	104 (11.8)	180 (9.4)		
Age and sex-adjusted HR (95% CI)	Reference	0.89 (0.71–1.12)	0.56 (0.46–0.67)	0.32	<0.001
Fully adjusted HR (95% CI) ^a	Reference	0.90 (0.71–1.14)	0.63 (0.51–0.76)	0.39	<0.001

Sustained physical activity: pivotal for best outcome

Supplemental Table S8. Changes in physical activity levels and risks for all-cause mortality, ESRD and MACE in chronic kidney disease patients


Change in Physical activity	N	All-cause mortality and ESRD			All-cause mortality			ESRD			MACE		
		E	Fully-adjusted HR (95% CI)*	p value	E	Fully-adjusted HR (95% CI)*	p value	E	Fully-adjusted HR (95% CI)*	p value	E	Fully-adjusted HR (95% CI)*	p value
Highly-Active													
Continually highly-active	1395	419	Reference		198	Reference		340	Reference		125	Reference	
Highly-active to less active [#]	274	66	1.39 (1.06-1.82)	0.017	44	2.20 (1.55-3.13)	<0.001	1	1.21 (0.84-1.75)	0.31	41	2.04 (1.32-3.14)	0.001
Low-Active													
Continually low-active	586	185	Reference		99	Reference		113	Reference		75	Reference	
Low-active to highly-active	23	2	0.99 (0.23-4.23)	0.99	1	0.83 (0.10-6.77)	0.86	1	1.22 (0.16-9.54)	0.85	3	1.51 (0.31-7.27)	0.61
Low-active to inactive	94	28	1.26 (0.81-1.95)	0.31	14	1.23 (0.66-2.32)	0.52	16	1.23 (0.68-2.24)	0.49	16	0.53 (0.22-1.28)	0.16
Inactive													
Continually inactive	1362	524	Reference		270	Reference		340	Reference		196	Reference	
Inactive to more active [†]	23	5	1.60 (0.65-3.92)	0.31	4	2.53 (0.91-7.05)	0.08	1	0.71 (0.10-5.15)	0.73	3	2.00 (0.61-6.52)	0.25

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; E, number of events; ESRD, end-stage renal disease; HR, hazard ratio; MACE, major adverse cardiac events; N, number of total patients

U-shaped association between of PA and MACE in CKD


A

All-cause mortality and ESRD




B

Major Adverse Cardiovascular Events




Outlines

- Physical activity (PA)
 - Benefit
- Muscle kidney crosstalk
- PA in CKD
 - Pathophysiology
 - Outcomes
- Interaction between PA and Cognitive Impairment in CKD





CKD and Cognitive Impairment





Cognitive impairment links to higher mortality in CKD

Cognition evaluated by **SPMSQ** (Short-portable mental-status questionnaire)




Joint association between cognitive impairment and PA



Mediation effects of PA in the relationship between cognitive impairment and the mortality risks


A

All-cause mortality



B

Cardiovascular mortality



$p <0.001$

$p <0.001$

Physical Activity: Protects Kidney, Heart and Brain in CKD

- Risk of physical inactivity are high both in CKD and non-CKD patients.
- Skeletal muscle-secretome (PGC-1 α , Irisin) reduces renal fibrosis
- Physical activity of **7.5 to <15 MET-h/week** is associated with lower risks of adverse cardiorenal outcomes
- Extremely-high physical activity may not be feasible in CKD patients.
- Physical activity interacts with cognitive impairment on mortality in elderly CKD patients.

Wei-Cheng Tseng, MD, PhD

wctseng@gmail.com

